Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.32%77 Days Sales Outstanding is 58.91 as of Mar. 2026, which is 4% below its 10-year median of 61.23. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Coloplast AS ranks better than 56.23% on this metric.
Coloplast AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was $707 Mil. Coloplast AS's Revenue for the
three
months ended in Mar. 2026 was $1,096 Mil.
Hence, Coloplast AS's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 58.91.
The historical rank and industry rank for Coloplast AS's Days Sales Outstanding or its related term are showing as below:
CLPBY'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.74 Med: 61.23 Max: 65.45
Current: 60.61
During the past 13 years, Coloplast AS's highest Days Sales Outstanding was 65.45. The lowest was 57.74. And the median was 61.23.
CLPBY's Days Sales Outstanding is ranked better than 56.23% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 66.24
vs CLPBY: 60.61
Coloplast AS's Days Sales Outstanding
declined
from Mar. 2025 (60.68) to Mar. 2026 (58.91).
Coloplast AS (OTCPK:CLPBY) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Coloplast AS Days Sales Outstanding Related Terms
Coloplast AS Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBY) has a Days Sales Outstanding of 58.91 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Coloplast AS and its competitors. This is near median its historical median of 61.23. Over the past decade, Coloplast AS's Days Sales Outstanding has ranged from 57.74 to 65.45. According to the industry distribution chart, Coloplast AS ranks #355 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 43.8%.
Is Coloplast AS's Days Sales Outstanding too high?
Coloplast AS's current Days Sales Outstanding of 58.91 is near median its 10-year median of 61.23. Over the past 10 years, this metric has ranged from a low of 57.74 to a high of 65.45. The Medical Devices & Instruments industry median Days Sales Outstanding is 66.24. Coloplast AS's value of 58.91 is 11.1% below this industry median. Based on the distribution chart, Coloplast AS ranks #355 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #355 out of 811 companies for Days Sales Outstanding. This puts Coloplast AS in the upper half of its industry. The industry median Days Sales Outstanding is 66.24. Coloplast AS's value of 58.91 is 11.1% below this benchmark. Historically, Coloplast AS's own Days Sales Outstanding has ranged from 57.74 to 65.45 over the past decade. While the company's 10-year median is 61.23 vs. the industry median of 66.24, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 66.24, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Days Sales Outstanding of 58.91 is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 66.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Days Sales Outstanding is 58.91, which is near median its own 10-year median of 61.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.71 — trading 48.6% below its estimated fair value. The current Days Sales Outstanding is 58.91, which is near median its 10-year median of 61.23 and 11.1% below the Medical Devices & Instruments industry median of 66.24. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Days Sales Outstanding is 58.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.71 is trading 48.6% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Days Sales Outstanding: 58.91 (near median its 10-year median of 61.23)
GF Value™: $13.05 vs. price of $6.71 (48.6% below fair value)
Industry Position: 11.1% below the Medical Devices & Instruments median (#355 of 811)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
